Semaglutide Reprograms Macrophages via the GLP-1R/PPARG/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth
Semaglutide modulates macrophage lipid metabolism through the GLP-1R/PPARG/ACSL1 signaling pathway. This modulation promotes the conversion of TAMs to the M1 macrophage phenotype, enhancing their anticancer activity. These findings suggest that semaglutide may improve therapeutic strategies, reduce unnecessary thyroid nodule screenings, and broaden its clinical applications.
Authors
- Runsheng Ma
- Qungang Chang
- Yifei Zhang (ORCID: https://orcid.org/0000-0002-8898-4870)
- Longlong Wang (ORCID: https://orcid.org/0000-0002-3932-1253)
- Lele Zhang (ORCID: https://orcid.org/0009-0007-1331-5086)
- Detao Yin (ORCID: https://orcid.org/0000-0002-4349-6857)
Institutions
- Zhengzhou University (CN)
- Henan Cancer Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1210/clinem/dgaf053
- Citations
- 13
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 12.17